PROLANZA olanzapine 15mg tablet blister pack

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

olanzapine, Quantity: 15 mg

Disponibbli minn:

Medis Pharma Pty Ltd

INN (Isem Internazzjonali):

Olanzapine

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; hyprolose; purified talc; lactose monohydrate; titanium dioxide; iron oxide yellow; xanthan gum; polyvinyl alcohol; iron oxide black; lecithin; indigo carmine aluminium lake

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

21, 60, 30, 7, 14, 28, 40, 10, 50, 20

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

For the treatment of schizophrenia and related psychoses. ,Alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. ,For preventing recurrence of manic, mixed or depressive episodes in Bipolar I Disorder.

Sommarju tal-prodott:

Visual Identification: Light blue, oblong, biconvex film coated tablets; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2011-08-11